Skip to main content

RETRACTION article

Front. Oncol., 19 October 2023
Sec. Molecular and Cellular Oncology
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1307333
This article is part of the Research Topic Cancer Stem Cell Differentiation: A Realistic Potential Therapeutic Option? View all 10 articles

Retraction: Exosomes from cancer-associated mesenchymal stem cells transmit TMBIM6 to promote the malignant behavior of hepatocellular carcinoma via activating PI3K/AKT pathway

This article is a retraction of:

  1. RETRACTED: Exosomes From Cancer-Associated Mesenchymal Stem Cells Transmit TMBIM6 to Promote the Malignant Behavior of Hepatocellular Carcinoma via Activating PI3K/AKT Pathway

    1. Read original article
Frontiers Editorial Office* Frontiers Editorial Office*

    A Retraction of the Original Research Article
    Exosomes from cancer-associated mesenchymal stem cells transmit TMBIM6 to promote the malignant behavior of hepatocellular carcinoma via activating PI3K/AKT pathway

    by Shang C, Ke M, Liu L, Wang C, Liu Y and Zheng X (2022) Front. Oncol. 12:868726. doi: 10.3389/fonc.2022.868726

    The Publisher retracts the cited article.

    Following publication, the publisher has discovered that the authors provided false information for the peer-review process. As the scientific integrity of the article cannot be guaranteed, and adhering to the recommendations of the Committee on Publication Ethics (COPE), the publisher therefore retracts the article.

    The authors have not responded to this retraction.

    This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers.

    Citation: Frontiers Editorial Office (2023) Retraction: Exosomes from cancer-associated mesenchymal stem cells transmit TMBIM6 to promote the malignant behavior of hepatocellular carcinoma via activating PI3K/AKT pathway. Front. Oncol. 13:1307333. doi: 10.3389/fonc.2023.1307333

    Received: 04 October 2023; Accepted: 04 October 2023;
    Published: 19 October 2023.

    Approved by:

    Luisa Lanfrancone, European Institute of Oncology (IEO), Italy

    Copyright © 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    *Correspondence: Frontiers Editorial Office, cmVzZWFyY2guaW50ZWdyaXR5QGZyb250aWVyc2luLm9yZw==

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.